

Garnet Health Clinical Trials
Clinical Trials
08/11/2023

Breast:

Study #	Title
A221803/ GH2212	Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
S2010/ GH2303	A Randomized Phase III Trial Comparing Active Symptom Monitoring + Patient Education vs. Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer

Gastrointestinal:

Study #	Title
NRG-GI008/ GH2210	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
S2107/ GH2213	Randomized Phase II Trial of Encorafenib & Cetuximab w//w/o Nivolumab for Pts w/ Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
A022104/ GH2302	The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet vs. Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

Genitourinary:

Study #	Title
S1802 HH1841	Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
S1806/ HH1957	Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
A031704/ HH1970	A Phase III Trial in Metastatic Untreated Renal Cell Cancer
NRG-GU010/ GH2202	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU008 HH2103	Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone & Apalutamide & Advanced Imaging into Salvage Treatment for Patients with Node+ Prostate Cancer After Radical Prostatectomy

Garnet Health Clinical Trials
Clinical Trials
08/11/2023

A032101/ GH2301	A Phase II Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer
--------------------	---

Head and Neck:

Study #	Title
EA3132/ HH1713	A Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head & Neck
EA3191/ HH2116	A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
EA3202/ GH2201	A Phase II/III Trial of Chemotherapy + Cetuximab vs. Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
EA3211/ GH2309	Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Lung:

Study #	Title
EA5181/ HH2017	Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
S2302/ GH2306	A Prospective Randomized Study of Ramucirumab + Pembrolizumab vs. Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent NSCLC